ArticleDigestive diseases and sciences2018
Impaired Quality of Life, Work, and Activities Among Adults with Clostridium difficile Infection: A Multinational Survey.
Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Omadacycline andThe Annals of pharmacotherapy · 2023Pooled it
- A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Role of the skilled nursing facility in Clostridioides difficile infection transitions of care: A retrospective cohort study of US hospitals.American journal of infection control · 2026Article
- Patient Satisfaction Scale Following a Laxative for Antibiotic Washout Prior to Oral Microbiome Therapy.Advances in therapy · 2025Article
- Retrospective, propensity score--matched study examining the relationship between frailty and Clostridioides difficile infection in a national cohort of US veterans.American journal of infection control · 2024Article
- Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.BMC infectious diseases · 2024Observational
- Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.Infectious diseases and therapy · 2024Article
- Interaction of Clostridioides difficile infection with frailty and cognition in the elderly: a narrative review.European journal of medical research · 2023Review
- Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With RecurrentOpen forum infectious diseases · 2023Article
- Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review.Infectious diseases and therapy · 2023Review
- The burden of CDI in the United States: a multifactorial challenge.BMC infectious diseases · 2023Review
- The Role of Bezlotoxumab for the Prevention of RecurrentAntibiotics (Basel, Switzerland) · 2022Review
- Clinical burden of recurrentAntimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- Health-related quality of life in patients with recurrentTherapeutic advances in gastroenterology · 2022Article
- Health care resource utilization and costs of recurrentJournal of managed care & specialty pharmacy · 2021Article
- A prospective, observational study of fidaxomicin use forThe Journal of international medical research · 2021Observational
- Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review.Health economics review · 2021Review
- Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey.Journal of patient-reported outcomes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence of humanistic detriments of Clostridium difficile infection (CDI) remains limited.
aimsTo assess humanistic burden associated with CDI.
methodsSelf-reported National Health and Wellness Survey data between 2013 and 2016 were analyzed for the USA, five European countries, China, and Brazil. Outcome measures included SF-36v2
resultsOf 352,780 respondents, 299, 2111, and 350,370 met the criteria for C-CDI, P-CDI, and NO-CDI, respectively, with 45% of the total from the USA. C-CDI and P-CDI respondents were older, were less often employed and had more comorbidities than those with NO-CDI. After adjustment for covariates, C-CDI and P-CDI had significantly lower HRQoL relative to NO-CDI for mental (MCS 39, 43 vs. 46) and physical (PCS 39, 41 vs. 46) component summary scores, and health utility (SF-6D 0.58, 0.64 vs. 0.71) (all p < 0.05), meeting common thresholds for minimally important differences. Those with C-CDI and P-CDI reported missing more work (21, 16 vs. 8%), greater impairment while working (43, 34 vs. 22%), and more activity impairment (61, 49 vs. 34%) than those with NO-CDI (all p < 0.05), respectively.
conclusionsCDI is associated with meaningfully worse HRQoL and greater impairment to work and activities compared with NO-CDI. The impairment directly attributable to CDI requires further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.